Mar 01, 2021 8:00am EST Algernon Pharmaceuticals to Conduct Phase 1 DMT Stroke Program Study with Hammersmith Medicines Research (UK)
Mar 01, 2021 7:00am EST Algernon Pharmaceuticals Appoints VP Research & Operations and Chief Medical Officer
Feb 25, 2021 7:00am EST Algernon Pharmaceuticals CEO to Speak at the Psychedelic Capital Virtual Investment Conference
Feb 19, 2021 8:00am EST Algernon Pharmaceuticals Awards DMT Manufacturing Contract to Dalton Pharma for Stroke Program
Feb 17, 2021 7:47am EST Algernon Pharmaceuticals Provides Update on COVID-19 Phase 2b Final Study Data
Feb 10, 2021 7:00am EST Algernon Pharmaceuticals Considers Adding Lung Scarring as an Additional Endpoint for its Phase 2b/3 COVID-19 Study Protocol
Feb 08, 2021 8:05am EST Algernon Pharmaceuticals Signs Agreement with Charles River Laboratories for DMT Preclinical Studies
Feb 03, 2021 8:00am EST Algernon CEO and CSO to Discuss New DMT Stroke Clinical Research Program Featured on BioPub Webcast Hosted by Dr. KSS MD, PhD
Feb 01, 2021 7:30am EST Algernon Pharmaceuticals Launches Stroke Treatment Clinical Research Program with Psychedelic Drug DMT “The Spirit Molecule”
